A case report of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with literature review

• by Dehui Kong, Man Yang, Xie Deng, ZiFan Xu, Hongqiong Duan, Guoqing Pan, Zi Lei

• June 2, 2026

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

• by Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu

• May 29, 2026

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

• by

• June 1, 2026

• 4 min

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

• by Lauren Averett Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, María Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young-Chul Kim, Luis Paz-Ares, Myung-Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy R. Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana

• June 1, 2026